March 26 (Reuters) - Sonnet Biotherapeutics Holdings Inc SONN.O:
SONNET BIOTHERAPEUTICS SUCCESSFULLY COMPLETES FIRST SAFETY REVIEW OF SON-1010 IN COMBINATION WITH TRABECTEDIN IN CERTAIN SARCOMAS
SONNET BIOTHERAPEUTICS HOLDINGS : SAFETY REVIEW COMMITTEE FOUND NO UNEXPECTED TOXICITIES IN EARLY DOSING OF SON-1010 IN FIRST 7 PATIENTS AT MTD
SONNET BIOTHERAPEUTICS : ANNUAL REVIEW SHOWED EXTENDED SAFETY OF SON-1010 MONOTHERAPY AT MTD WITH CLINICAL BENEFIT IN 83% OF PATIENTS AT THAT DOSE
Source text: ID:nGNX89JD06
Further company coverage: SONN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.